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Antagonists of glutamate receptors of the N-methyl-D-aspartate
subclass (NMDAR) or inhibitors of nitric oxide synthase (NOS)
prevent nervous system plasticity. Inflammatory and neuropathic
pain rely on plasticity, presenting a clinical opportunity for the use
of NMDAR antagonists and NOS inhibitors in chronic pain. Agma-
tine (AG), an endogenous neuromodulator present in brain and
spinal cord, has both NMDAR antagonist and NOS inhibitor activ-
ities. We report here that AG, exogenously administered to ro-
dents, decreased hyperalgesia accompanying inflammation, nor-
malized the mechanical hypersensitivity (allodyniayhyperalgesia)
produced by chemical or mechanical nerve injury, and reduced
autotomy-like behavior and lesion size after excitotoxic spinal cord
injury. AG produced these effects in the absence of antinociceptive
effects in acute pain tests. Endogenous AG also was detected in
rodent lumbosacral spinal cord in concentrations similar to those
previously detected in brain. The evidence suggests a unique
antiplasticity and neuroprotective role for AG in processes under-
lying persistent pain and neuronal injury.
Agmatine (AG) is formed by the enzymatic decarboxylationof L-arginine (1). It has been discovered recently in mam-
mals (2, 3), where it is expressed in the central nervous system.
In brain, AG meets most of the criteria of a neurotransmittery
neuromodulator (4): it is synthesized, stored, and released from
specific networks of neurons (5, 6), is inactivated by energy-
dependent reuptake mechanisms (7), is degraded enzymatically
(8), and binds with high affinity to a2-adrenergic and imidazoline
(I1) receptors (2, 9). In addition, AG antagonizes N-methyl-D-
aspartate receptors (NMDAR) (10) and inhibits all isoforms of
nitric oxide synthase (NOS) (11, 12). NMDAR antagonists and
NOS inhibitors prevent adaptive changes in neuronal function,
including opioid tolerance (13, 14), persistent pain (15–17), and
spinal cord injury (SCI) (18–21). Therefore, AG, which antag-
onizesyinhibits both NMDAR and NOS, should moderate
chronic pain accompanying inflammation, neuropathy or SCI.
We report here that AG, when exogenously administered,
selectively relieves allodynic, hyperalgesic, and autotomy-like
states accompanying spinal nerve injury, peripheral inflamma-
tion, and excitotoxic SCI, respectively. Moreover, as in brain (5,
6), we have detected AG in spinal cord, indicating that AG may
be an endogenous modulator of pain pathways.
Methods
Animals. Institute of Cancer Research mice (25–30 g, Harlan,
Teklad, Madison, WI), Sprague–Dawley rats [125 g, Harlan
Teklad (Fig. 1D; 400–500 g, Harlan Teklad (Fig. 5C); 200–
250 g, Charles River Breeding Laboratories (Figs. 3 and 4)]. All
experiments were approved by the Institutional Animal Care and
Use Committees. Each group had at least five animals; each
animal was used only once.
Chemicals. The following chemicals were used: MK801 (Merck);
LY235959 (Lilly Research Laboratories, Indianapolis); carra-
geenan (CARRA), ketamine, dextromethorphan, ifenprodil,
aminoguanidine, Nv-nitro-L-arginine methyl ester (L-NAME), AG,
NMDA, substance P (SP), memantine, and a-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid (AMPA)ymetabotropic agonist
quisqualate (QUIS; Sigma); dynorphin (DYN; National Institute
on Drug Abuse), SK&F 86466 (SmithKline Beecham), efaxoran
(Research Biochemicals), and moxonidine (Solvay Pharma). SP
and moxonidine were dissolved in acidified saline; CARRA was
dissolved in PBS; and all the other drugs were dissolved in 0.9%
normal saline.
Mechanical Sensitivity Testing. Application of von Frey (vF) fila-
ments 2.44 (0.4 mN, innocuous) and 3.61 (3.3 mN, noxious)
cause mice to lick, withdraw, andyor shake the paw, actions
representing a behavioral endpoint. In Figs. 1 and 2, nociception
was tested by multiple vF applications to the plantar (Figs. 1 A
and 2 C–F, 10 applications) or dorsal (Fig. 2 A and B, 6
applications) hindpaw surfaces.
CARRA-Evoked Mechanical Hyperalgesia. Intraplantar injections of
CARRA (4%y50 ml), or PBS (50 ml) were given to halothane-
anesthetized mice. After confirmation of hyperalgesia at 3 h
postinjection, AG or SAL was delivered intrathecally (i.t.),
followed by continued testing for mechanical sensitivity.
CARRA-Evoked Muscle Hyperalgesia. Intramuscular (triceps) injec-
tions of CARRA (4 mgy75 ml), but not PBS (75 ml), in
halothane-anesthetized rats produced hyperalgesia, which was
indicated by a decrease in forelimb grip tensile force (22) at 12 h
after CARRA. AG or SAL then was delivered i.t., followed by
continued testing. The data are pooled from three experiments
conducted by a blinded observer.
Dynorphin-Induced Allodynia. Intrathecal injections of DYN (3
nmol) or SAL (5 ml) were given to awake mice. After confir-
mation of allodynia at 1 day postinjection, AG or SAL was
delivered i.t., followed by continued testing for mechanical
sensitivity by a blinded observer.
Nerve Injury-Induced Hypersensitivity. Spinal nerve ligation induces
mechanical hypersensitivity of the ipsilateral hindpaw in mice
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(24, 25). In halothane-anesthetized mice, the left paraspinal
muscle (at the level of the lumbrosacral spinal nerves L4–S2) and
the L6 transverse process were removed. The L5 spinal nerve was
ligated (6-0 silk thread) distal to the dorsal root ganglion and
proximal to the L4-L5 spinal nerve confluence. Control groups
included naı¨ve or sham-operated (no nerve ligation) mice. After
induction of allodyniayhyperalgesia was confirmed, AG or SAL
was injected followed by continued testing for mechanical sen-
sitivity by blinded observers.
SCI. QUIS (125 nmol) or QUIS 1 AG (1, 5, and 10 nmol) was
injected (1 ml) in anesthetized rats 900 mm below the dorsal
surface of the spinal cord in laminae IV–VI.
Histology. After 3 days, rats were perfused transcardially
(saline, then 10% formalin) and cords were removed for histol-
ogy. Spinal cord cross-sections (75 mm) were examined with light
microscopy, and reconstructions of the lesion were made with an
overhead projector and camera lucida. Areas of tissue damage
eight sections rostral and eight sections caudal (1,275 mm total
length) to the lesion epicenter were measured by using a
computer-aided imaging system (26) (IMAGE 1; Universal Imag-
ing, Media, PA). Comparing the area of normal gray matter
between each 75-mm section and the corresponding segmental
level of uninjured control cords yielded a longitudinal profile of
the percentage of gray matter damage in the injured cord. To
obtain an overall descriptor of the amount of tissue damage, the
total lesion volume was calculated by subtracting the volume of
gray matter remaining in injured animals from the normal
control volume. AG was given either (i) intraspinally at the time
of QUIS administration (Fig. 3) or (ii) systemically (100 and 150
mgykg, i.p.) 30 min after QUIS administration and once daily
thereafter for 3 days (Fig. 4).
Behavior. The area of skin with evidence of excessive grooming
was measured and compared between QUIS- and QUIS 1
AG-treated groups (Student’s t test.). In these studies, AG was
delivered systemically (100 mgykg, i.p.) either (i) 30 min after
QUIS and once daily thereafter for 14 days or (ii) 14 days after
QUIS (after onset of the behavior) and once daily thereafter for
14 days.
Tail Flick Tests. Antinociception. Antinociception was tested by
tail immersion in warm water (52.5°C), and the latency to rapid
tail f lick was measured (3.61 6 0.17 s, n 5 36). For this test,
percent antinociception was calculated as percent maximum
possible effect by the formula: (postdrug latency 2 predrug
latency)y(12 2 predrug latency) 3 100%.
NMDA-evoked thermal hyperalgesia (NMDA hyperalgesia). Tail
flick latency to radiant heat was measured before and 1, 3, and 10
min after NMDA (0.15 nmol, i.t.) (27). Data are expressed as the
average percent inhibition 6 SEM during this time period by the
formula: [(ControlD 2 ExperimentalD)yControlD] 3 100%. ED50
values were calculated by the method of Tallarida and Murray (28).
NMDA and SP Tests. Transmitter-induced behavior tests compare
the number of hindlimb-directed behaviors elicited within 1
(mouse) or 1.5 (rat) min after i.t. delivery of SP (29) or NMDA
(30). SP (15 ng i.t.) produces biting and scratching behavior (SP
behavior) in mice (n 5 12, 68 6 9.0 behaviors). NMDA (0.3
nmol) elicits biting behavior in mice (n 5 18, 56 6 4.3) and
nociceptive behaviors (spontaneous tail f licks and rapid circling)
in rat (n 5 10, 33.5 6 5.4). AG was tested for inhibition of
behaviors elicited by both SP (mice) and NMDA (mice, rats).
MK801, ketamine, dextromethorphan, ifenprodil, memantine
aminoguanidine, LY235959, and L-NAME also were tested for
inhibition of NMDA behavior (mice). For these tests, percent
antinociception was calculated as percent inhibition 6 SEM by
the formula [(Control 2 Experimental)yControl] 3 100%.
Electrophysiology. Spinal L3-L5 laminectomy permitted extracel-
lular single-neuron recordings in urethane-anaesthetized (1.2
gykg i.p.) male rats (450 g, 38°C) via the center barrel (2 MV
carbon) of seven-barreled glass microiontophoretic electrodes:
50 mM NMDA (pH 8.0) and 15 mM AG (pH 6.5), both in 150
mM NaCl, administered with automatic current balancing. Re-
cordings were made from dorsal horn neurons responding to
noxious or to both innocuous (brush) and noxious (pinch,
squeeze) stimuli applied to the ipsilateral hindpaw receptive
fields. Peristimulus time histograms of action potentials evoked
by iontophoretic application of NMDA (20 neurons) or natural
stimulation (vide infra) of the cutaneous receptive field involved
detection (window discriminator) and accumulation (computer).
Receptive fields of three spinal neurons were activated by
cutaneous stimulation (vF 5.18, 140 mN, 0.5–1 Hz or no. 1
paintbrush, 1–5 min on, 1–5 min off, repeatedly for 15–30 min).
Rotarod Assay. After two training sessions, mice walked for 300 s
on an accelerating (4–40 rpm) rotarod (Ugo Basile, Varese,
Italy). We compared the latency to fall before (291 6 5.4 s, n 5
48) and after delivery (i.t.) of saline or drug (MK801, L-NAME,
AG) by the formula: % motor impairment 5 (predrug latency
2 postdrug latency)y(predrug latency) 3 100%. Mice that
walked for 300 s were scored 100%.
HPLC. The HPLC method (31) used was modified from two
reports (3, 32). Tissue extracts (32) were concentrated under
vacuum and suspended in 75 ml of borate buffer (pH 9.4)
containing 2-p-toluyl ethyl amine (internal standard). NaCN (25
ml, 10 mM) was added, followed by naphthalene dicarboxalde-
hyde (NDA; 200 ml, 1 mM) in MeOH for derivatization (at room
temperature for 4 min). Three to 50 ml of the reaction mixture
was injected onto a 250 3 4.6-mm Alltech Associates Nucleosil
C8 10-mm HPLC cartridge and eluted (flow rate: 1.5 mlymin)
with 55% acetonitrile in a buffer (3.42 g KH2PO4 and 4.32 g
K2HPO4 in 1 liter of HPLC-grade H2O, pH 6.81).
Immunocytochemistry. Naı¨ve rats or mice were perfused (4% para-
formaldehydey0.2% picric acidy0.1 M PBS, pH 6.9), and brains or
spinal cords were removed for histology (33). Primary antisera or
preimmune serum was incubated overnight (4°C) on 14-mm brain
or lumbar spinal cord cross-sections at the following dilutions:
rabbit anti-AG, 1:50 (D.J.R.); mouse anti-NeuN (antineuronal
nuclear protein), 1:500; and mouse antidopamine-b-hydroxylase,
1:500 (Chemicon). Double-labeled slides were visualized with a
mixture of fluorescein isothiocyanate and lissamine-rhodamine-
conjugated secondary antisera 1:200 (Jackson ImmunoResearch).
Spinal cord sections (n $ 3 animals per experiment) were examined
with a MRC-1000 Confocal Imaging System (Bio-Rad). Fields were
selected to represent the pattern of AG-LI when single-labeled or
in relation to NeuN or dopamine b-hydroxylase (DbH).
Results
Inflammatory and Neuropathic Pain Models. To test the effect of AG
on persistent pain, AG was delivered after inflammation and
nerve injury. Intrathecal AG (60 nmol) reversed preestablished
CARRA mechanical (mice, Fig. 1 A and B) and muscle (rats, Fig.
1 C and D) hyperalgesia. AG did not affect responses of
PBS-treated rats, which were comparable to PBS-SAL controls.
We also tested AG’s impact on neuropathic pain elicited by
dynorphin or ligation of a peripheral nerve. A single injection of AG
(0.3 nmol, i.t.) reversed dynorphin allodynia (23) for at least 28 days
(Fig. 2 A and B, 1–21 days). The a2yI1 agonist moxonidine only
transiently inhibited (2 h) allodynia (data not shown), suggesting
that the persistent AG effect does not likely involve a2yI1 receptors.
AG reversal of allodynia was observed in another mouse
model of neuropathic pain [Chung Model (24)]. L5 spinal nerve
injury induced hypersensitivity of the ipsilateral hindpaw (Fig. 2
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C–F). A single injection of AG (0.3 nmol, i.t.) reversed this
allodynia (Fig. 2C, 2 weeks) and hyperalgesia (Fig. 2E, 3 weeks).
Responses did not increase throughout the test period in naı¨ve
or sham-operated mice (AG-treated or SAL-treated, data not
shown). Again, in contrast to AG, moxonidine only transiently
(2 h) inhibited hyperalgesia (25). These results demonstrate that
AG (i.t.) decreases established hypersensitivity induced by in-
flammatory, chemical, and mechanical insults in rodents.
SCI. To determine the effects of AG on neuronal damage, AG
was given either concurrently or after intraspinal QUIS injec-
tion. QUIS (Fig. 3A) produced excitotoxic injury similar to that
associated with ischemic and traumatic SCI (34, 35). Intraspi-
nally administered AG (1–10 nmol, Fig. 3 B–E) injected with
QUIS reduced the lesion. Pathological effects of intraspinal AG
alone were not evident at these doses (data not shown). AG
administered systemically (100, 150 mgykg, i.p.) 30 min after
QUIS (Fig. 4 A–C) significantly reduced the lesion (Fig. 4D).
QUIS also causes delayed (’2 weeks) excessive grooming be-
havior directed to specific measurable areas of dermatomes
corresponding to the lesion. AG (100 mgykg, i.p. 30 min post-
QUIS) significantly reduced the grooming area (QUIS, 9.75 6
1.9; QUIS 1 AG, 0.98 6 0.7 cm2, Student’s t test). AG (100
mgykg i.p., once daily for 14 days beginning after establishment
of the grooming behavior, ’2 weeks post-QUIS) also reduced
the grooming area (QUIS, 7.9 6 1.2; QUIS 1 AG, 1.3 6 0.45
cm2, Student’s t test).
Antinociception. To determine whether AG is antinociceptive, we
tested for inhibition of responses to noxious thermal and chem-
ical stimuli. AG (i.t.) neither prolonged tail f lick latencies nor
inhibited SP behavior (Fig. 5A). These results do not support an
antinociceptive action for AG.
Fig. 1. Inflammation. (A and C) Time course of AG or SAL treatment (i.t.)
after inflammation-induced hyperalgesia. The duration of hypersensitivity
was compared among CARRA 1 SAL, PBS 1 SAL, and CARRA 1 AG. (B and D)
Area under the curve (AUC; average across time) showing dose-related inhi-
bition of hyperalgesia by AG. Included data coincide with times when prelim-
inary studies had revealed significant differences between CARRA- and PBS-
treated groups. The percent inhibition was calculated from the equation
[(Control 2 Experimental)yControl] 3 100%, and * indicates a statistically
significant difference (ANOVA with Bonferroni) between the SAL-injected
control and AG-treated groups (doses at and below the most effective inhib-
itory dose). These experiments were replicated and produced comparable
results. (A) Mechanical hyperalgesia. Three hours after CARRA injection into
the hindpaw, mice showed increased responses () compared with PBS-
injected controls (figchr;E) (P # 0.001, Student’s t test). AG (60 nmol, i.t.)
(figchr;) injected 3 h after CARRA reduced hyperalgesia. The * indicates a
statistically significant difference (ANOVA-repeated measures with Bonfer-
roni). (B) AUC (15, 30, and 45 min) after AG injection. (C) Muscle hyperalgesia.
Twelve hours after CARRA injection into the triceps, rats showed decreased
grip force () compared with PBS-injected controls (E) (P # 0.001, Student’s t
test); AG (60 nmol, i.t.) () injected 12.5 h after CARRA reduced hyperalgesia.
(D) AUC (12.5, 18, and 24 h after CARRA injection).
Fig. 2. Neuropathic pain models. (A, C, and E) Time course of AG () or SAL
() treatment (i.t.) after induction of hyperalgesia representing neuropathic
pain. The duration of hypersensitivity was compared among injured (),
vehicle-treated or sham-operated (V), or naı¨ve () mice. (B, D, and F) AUC
showing dose-related inhibition of hyperalgesia by AG. Data analysis is iden-
tical to that described for Fig. 1 B and D. These experiments were replicated
and produced comparable results. (A) Dynorphin allodynia. DYN-treated mice
show increased responsiveness () compared with SAL-injected controls (V)
(P # 0.0001, Student’s t test). AG (0.3 nmol) () injected 1 day after DYN
reduced allodynia. (B) AUC (days 2, 3, and 7 after DYN injection). Spinal nerve
injury. (C) Allodynia. Nerve-injured mice showed increased responses ()
compared with sham-operated (V) or naı¨ve () controls (ANOVA, P # 0.001).
AG (0.3 nmol) () injected 1 day after surgery reduced allodynia. (D) AUC (2,
3, 5, 7, and 14 days after ligation). (E) Hyperalgesia. Three days after surgery,
nerve-ligated mice showed increased responses () compared with sham-
operated (V) or naı¨ve () controls; AG (0.3 nmol) () injected 1 day after
surgery reduced hyperalgesia. (F) AUC (5, 7, 14, and 21 days after ligation).
Fig. 3. (A–E) Concurrent intraspinal AG reduces QUIS-induced SCI. (A) QUIS (125
nmol). (B) QUIS (125 nmol) 1 AG (1 nmol). (C) QUIS (125 nmol) 1 AG (5 nmol). (D)
QUIS (125 nmol) 1 AG (10 nmol). (E) AG-treated spinal cords (5 nmol) showed
significantly less damage than those exposed to QUIS alone (ANOVA, P , 0.05).
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NMDA Behavior. To test for AG-mediated NMDAR blockade in
vivo, we coadministered AG with NMDA (i.t.). AG antagonized
NMDA behavior in mouse (ED50 5 30, 18–50 nmol, Fig. 5A) and
rat (ED50 5 19, 4–85 nmol, data not shown), but not AMPA-
evoked behavior in mice (0.3 nmol, data not shown). Other
NMDAR antagonists (ED50: ketamine, 0.1, 0.48–0.21; memantine,
0.16, 0.085–0.31; dextromethorphan, 0.6, 0.37–1.0; MK801, 0.92,
0.5–1.7; ifenprodil, 0.17, 0.07–0.39 nmol i.t.; LY235959, 0.06, 0.02–
0.16 pmol i.t.) inhibited NMDA behavior with significantly greater
potency than AG. Whereas the nonselective NOS inhibitor L-
NAME did not inhibit NMDA behavior (0.1–10 nmol i.t., data not
shown), the selective iNOS inhibitor aminoguanidine did (ED50:
0.3, 0.14–0.62 nmol i.t.), suggesting that, like AG, aminoguanidine
may antagonize NMDAR. Because AG binds to a2-adrenergic
receptors (ARs) (36) and I1 receptors (2), we also tested antagonists
selective for a2-AR (SK&F 86466) and a2yI1 (efaroxan) for antag-
onism of AG-induced inhibition of NMDA behavior. Neither
antagonist interfered with the action of AG in this test, indicating
that a2yI1 receptors are not involved.
NMDA Hyperalgesia. To test AG for inhibition of NMDA hyper-
algesia, we compared AG with MK801 and L-NAME (27).
NMDA decreased (P , 0.0001, Student’s t test) tail f lick
latencies (3.1 6 0.1 s, n 5 9) relative to SAL controls (4.4 6
0.15 s, n 5 9) (27). MK801 inhibited this hyperalgesia with a
potency (ED50: 2.6 nmol, 0.96–4.8) comparable to that of its
inhibition of the corresponding nociceptive behavior (ED50:
1.6 nmol, 0.92–2.7) measured in the same mice. This result
confirms that both of MK801’s behavioral actions rely on
NMDAR activation. Coadministration of L-NAME (550 nmol,
i.t.) with NMDA fully prevents NMDA hyperalgesia (27) with
only partial (43%) inhibition of NMDA behavior (present
study). This result indicates that NOS may contribute more to
thermal hyperalgesia than to nociceptive behavior. Interest-
ingly, AG inhibits the thermal hyperalgesia at significantly
lower doses (ED50: 0.45 nmol, 0.089–2.2) than those required
to inhibit the corresponding nociceptive behavior (ED50:
53 nmol, 25–112, Fig. 5B). This discrepancy supports the
proposal that, at the lower doses, AG may act at another
effector (e.g., NOS) to prevent the hyperalgesia.
NMDA-Evoked Firing. Consistent with these behavioral studies,
iontophoretically (37) applied AG inhibited NMDA-evoked
firing in 7 of 20 rat spinal neurons studied (Fig. 5C) but did not
change activity evoked by physiological stimulation of cutaneous
receptive fields, a result consistent with lack of AG-induced
inhibition of spinal nociceptive reflexes (38). Failure of AG to
inhibit physiologically evoked responses is in agreement with its
apparently selective action at NMDAR and minimal inhibition
of AMPA-evoked current (10) and behavior (data not shown).
Presumably, activity evoked synaptically from glutamatergic
afferent axons activates secondary sensory neurons by using both
receptor subtypes.
Rotarod Test. Acute delivery of MK801 impaired motor function
with an ED50 (11 nmol, 6.3–18) 4-fold higher than the antihy-
peralgesic ED50 (2.6 nmol, 0.96–4.8). Motor function was not
affected by L-NAME (550 nmol, i.t.) or AG (0.3–240 nmol, i.t.),
suggesting that (using this test) the therapeutic index of spinally
administered AG is substantially higher than that of MK801.
Endogenous AG in Rodent Spinal Cord. AG levels in naı¨ve and
saline-treated (5 ml, i.t.) mouse lumbosacral spinal cord were
0.96 6 0.14 and 0.56 6 0.2 mgyg wet weight (n 5 4–5),
respectively, values similar to those reported in mammalian brain
(2, 32). Intrathecally administered AG (60 but not 0.3 nmol)
significantly increased spinal AG levels (2.6 6 0.65 mgyg wet
weight, n 5 6, ANOVA, P , 0.05).
Spinal AG was immunocytochemically localized with AG
antiserum. Preincubation of the antiserum with free AG (but not
structurally related compounds arginine, spermidine, spermine,
ornithine, putrescine, or citrulline) inhibited binding to conju-
Fig. 4. (A–D) Systemic AG reduces QUIS-induced SCI. (A) QUIS (125 nmol). (B) QUIS (125 nmol) 1 AG (100 mgykg). (C) QUIS (125 nmol) 1 AG (150 mgykg). (D)
AG-treated (30 min after QUIS) spinal cords showed significantly less damage than those exposed to QUIS alone (ANOVA, P , 0.05).
Fig. 5. (A–C) Acute nociceptive tests. (A) AG was inactive in the tail flick (10-min pretreatment) and SP (coadministered) behavioral tests. AG inhibited NMDA
behaviors (ED50: 30 nmol, 18–50). (B) NMDA hyperalgesia and nociceptive behavior. AG inhibited NMDA hyperalgesia with greater potency (ED50: 0.45 nmol,
0.089–2.2) than inhibition of NMDA behavior in the same animals (ED50: 53 nmol, 25–112). (C) NMDA-evoked firing. Iontophoretically applied AG inhibited
NMDA-evoked firing in 7 of 20 NMDA-responsive dorsal horn neurons tested.
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gated agmatine (5, 39). The antiserum specificity was confirmed
for the conditions used in these studies. Neurons were identified
by using neuronal marker NeuN (40) (Fig. 6 A and B). AG-like
immunoreactivity (AG-LI) was associated with cingulate cortical
neurons (Fig. 6C) as shown previously (5), was not observed in
tissue incubated with preimmune serum (data not shown), and
was concentration-dependently decreased after preincubation of
antiserum with free AG (0.1, 1, and 10 mM, data not shown; 100
mM, Fig. 6D). AG-LI (fibers andyor puncta) was sparsely but
consistently observed in all areas of the mouse spinal cord gray
matter (Fig. 7A); fibers also were present in the surrounding
white matter. At higher magnification, AG-LI was observed
surrounding NeuN immunoreactivity lateral to the central canal
in sacral spinal cord sections (Fig. 7B). AG’s association with
a2AR and I1 receptors implied a common source with norepi-
nephrine; therefore, we compared AG-LI with that of DbH, a
marker for noradrenergic terminals. High magnification showed
that AG-LI fibers were distinct from DbH-containing processes
(Fig. 7C), suggesting independent sources for AG and norepi-
nephrine.
Discussion
The localization of AG and its synthetic and degradative en-
zymes in mammalian brain (2) established a potentially novel
neurotransmitter (4). The characterization of its dual-activity
profile, NMDAR antagonism (10) with NOS inhibition (11, 12),
may have equal impact in several areas of neuroscience relating
to glutamatergic neurotransmission and synaptic plasticity. This
report shows modulation by exogenous AG of spinally mediated
pain states that depend on glutamate receptors and neuronal
plasticity.
The present experiments reveal the ability of AG to restore
injured, hypersensitive mice to normal levels of sensation. In-
trathecally administered AG reversed CARRA mechanical and
muscle inflammatory hyperalgesia. These actions were dose-
dependent, transient (1–6 h, consistent with ref. 41), and com-
parable in efficacy to levorphanol, dexamethasone, and indo-
methacin (22). A single posttreatment of AG (0.3 nmol, i.t.)
persistently reversed long-lasting hypersensitivity induced by two
models of neuropathic pain: dynorphin, i.t. (23, 42), or nerve
injury (Chung Model; ref. 24). AG efficacy in the Chung Model
is notable because it is a widely accepted neuropathic pain
model, corresponding well with clinical observations (43). AG’s
moderation of neuropathic pain is consistent with the antihy-
peralgesic activity of an analog of histogranin, another endog-
enous NMDAR antagonist (16). However, AG’s reversal is
persistent and possibly reliant on an additional action other than
NMDAR antagonism.
Traumatic SCI also induces chronic pain (44) and may invoke
common, secondary pathological cascades, including activation
of NMDAR (26, 45), AMPAykainate receptors (46), and NOS
(44). AG reduced QUIS-induced spinal gray matter injury when
administered intraspinally (34) or systemically (i.p.) 30 min after
QUIS. Systemic, daily AG treatment also reduced autotomy-like
behavior whether started 30 min or 14 days after QUIS (after
establishment of the behavior). These data concur with evidence
showing that AG (i.p.) prevented ischemia-induced neuronal
loss (47). AG’s reduction of hypersensitivity and SCI demon-
strates a postinjury therapeutic potential in multiple preclinical
models of persistent pain.
The effects of AG in these neuropathic pain models are
distinctly antiallodynic and antihyperalgesic. Agents such as
morphine and clonidine, which transiently relieve allodyniay
hyperalgesia, are also analgesic in normal subjects; in contrast,
AG did not modify nociceptive responses to acute thermal (48),
chemical, or mechanical (data not shown) stimuli. These results
agree with evidence that NMDAR antagonists and NOS inhib-
itors are not antinociceptive (49) and distinguish AG from
conventional analgesics.
AG inhibits NMDA-evoked currents in cultured rodent hip-
pocampal neurons by channel blockade (10). The present report
extends this finding to show that AG blocks spinal NMDARs by
inhibition of both NMDA behavior and firing in spinal neurons.
Consequently, AG may reverse spinal hypersensitivity through
NMDAR antagonism, in agreement with evidence that NMDAR
antagonist pretreatment prevents the induction of CARRA-
Fig. 6. AG-LI in rat cortex. Single, 14-mm coronal sections were single- or
double-labeled with AG (red) and NeuN (green) antisera. (A) AG-LI associated
with NeuN-positive cells (arrows). (Bar 5 200 mm.) (B) The boxed portion of A
at higher magnification projected from eight optical sections acquired at
1-mm intervals by using a 360 objective. (Bar 5 5 mm.) (C) AG-LI in cingulate
cortex. (Bar 5 50 mm.) (D) Absence of AG-LI in cingulate cortex after preab-
sorption with free AG (100 mM). (Bar 5 50 mm.)
Fig. 7. AG-LI in mouse spinal cord. Single, 14-mm cross-sections were single-
or double-labeled by using antisera to NeuN (green) or DbH (green, norad-
renergic) and AG (red). Double-labeled micrographs represent projected im-
ages from multiple optical sections (o.s.) acquired at 1-mm intervals using a
360 objective and confocal zoom. (A) AG-LI in dorsal horn is in a few fibers; the
midline is on the left. (Bar 5 200 mm.) (B) Area dorsolateral to central canal: AG
and NeuN (5 o.s.). (Bar 5 5 mm.) (C) Lumbar dorsal horn: AG and DbH (6 o.s.).
(Bar 5 5 mm.)
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induced (50, 51), DYN-induced (23, 42), and nerve injury-induced
(15) hypersensitivity. The doses necessary for temporary reversal of
inflammation-induced hyperalgesia (60 nmol, i.t.) and for protec-
tion from excitotoxic injury (5 nmol, intraspinally) are comparable
to the doses (30–60 nmol, i.t.) required to inhibit NMDA behavior.
This correspondence suggests that these three effects of AG require
NMDAR antagonism.
That the doses necessary for reversal of neuropathic pain (0.3,
1 nmol, i.t.) and NMDA hyperalgesia (0.4 nmol, i.t.) are 100-
times lower than those required to antagonize NMDAR-
mediated behavioral actions (30–60 nmol, i.t.) suggests that the
mechanism for AG-mediated recovery from neuropathic pain
requires activity other than NMDAR blockade. NMDA hyper-
algesia relies on NOS activation (27), and AG inhibits all
isoforms of NOS (12). We speculate that NOS inhibition,
concerted action at both NMDAR and NOS, or some unknown
action mediates these high-potency actions. AG’s low potency
against NMDA behavior, 30- to 500,000-times lower than those
of clinically (ketamine, memantine, dextromethorphan) and
experimentally (MK801, aminoguanidine, ifenprodil,
LY235959) used NMDAR antagonists, may be predictive of an
improved therapeutic potential for AG relative to previously
used agents (14, 52, 53).
AG’s exogenous profile suggests that endogenous AG could
play a similar role. Endogenous control of spinal plasticity by AG
would require localization in spinal tissue. Immunocytochemis-
try (5), electron microscopy (5), and HPLC (2, 3) previously have
identified AG in brain. AG-LI has been observed in association
with small synaptic vesicles in axons and axon terminals (6) in
hippocampus, suggesting a neuronal source of AG in the central
nervous system. We report AG levels in spinal cord consistent
with previously reported values in brain. Additionally, the lo-
calization of AG-LI in spinal cord is suggestive of a neuromodu-
latory role for AG. Further studies are warranted to determine
whether endogenous AG participates in the spinal processing of
plasticity associated with persistent pain syndromes.
Exogenous administration of AG hours to days after injury
significantly reduces pain induced by inflammation, neuropathy,
and SCI, suggesting a new therapeutic direction for plasticity-
mediated neurodysfunction. Several reports describe the phe-
nomena that exogenous AG pretreatment reduces the develop-
ment of opioid tolerance (48, 54), inflammation-induced ther-
mal hyperalgesia (41), and ischemia-induced neuronal lesion
(47). The present study demonstrates an endogenous location
and potential mechanisms for AG-mediated antiplasticity action
in spinal cord postinjury. The apparently low toxicity and
selective antihyperalgesic (nonanalgesic, nonsedating) profile of
AG make the compound a novel and potentially advantageous
therapeutic agent for treatment of chronic pain and SCI.
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